The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Ole Jakob Storebø*, Erlend Faltinsen, Morris Zwi, Erik Simonsen, Christian Gluud

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftKommentar/debatForskning

Abstrakt

Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.

OriginalsprogEngelsk
Sider (fra-til)606-609
Antal sider4
TidsskriftClinical Pharmacology and Therapeutics
Vol/bind104
Udgave nummer4
DOI
StatusUdgivet - okt. 2018

Fingeraftryk

Udforsk hvilke forskningsemner 'The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder' indeholder.

Citationsformater